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Abstract: The ability to efficiently establish a new infection is a critical property for human immun-
odeficiency virus type 1 (HIV-1). Although the envelope protein of the virus plays an essential role in
receptor binding and internalization of the infecting virus, the structural proteins, the polymerase
and the assembly of new virions may also play a role in establishing and spreading viral infection
in a new host. We examined Ugandan viruses from newly infected patients and focused on the
contribution of the Gag-Pol genes to replication capacity. A panel of Gag-Pol sequences generated
using single genome amplification from incident HIV-1 infections were cloned into a common HIV-1
NL4.3 pol/env backbone and the influence of Gag-Pol changes on replication capacity was monitored.
Using a novel protein domain approach, we then documented diversity in the functional protein do-
mains across the Gag-Pol region and identified differences in the Gag-p6 domain that were frequently
associated with higher in vitro replication.
Keywords: HIV-1; Uganda; recombinant; Gag-Pol; protein domains
1. Introduction
During early HIV-1 infection, viremia increases rapidly, reaching a peak within weeks
of infection, then drops to a level (the set point viral load or SPVL) that can remain stable
over months to years of asymptomatic infection [1]. High SPVL is a predictor of faster
disease progression [2]. The determinants of SPVL are complex and involve the host’s
immune system as well as properties of the infecting virus and have been a matter of
intensive research. SPVL and viral control vary by infecting subtype, with subtype A
associated with control [3,4]. Subtype D HIV-1 infections have an increased frequency of
CXCR4 co-receptor usage [5,6] and faster CD4+ T cell decline [7], which could account
for the more aggressive clinical course HIV-1 subtype D infections than subtype A in
sub-Saharan Africa [6,8–11].
Several studies report that the initial viruses establishing new HIV-1 infections may be
important determinants of SPVL [12] and disease progression [13]. High viral replicative
capacity (VRC) of transmitted HIV-1 among subtype C viruses has been associated with
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faster progression to disease [14,15]. Baalwa suggested that early subtype D viruses
replicate more efficiently than subtype A [16] and subtype C viruses have lower VRC
compared to other subtypes [17–19]. We asked if there were differences in VRC among
Ugandan HIV-1 early viruses of subtypes A and D and their recombinants and set out
to identify virus sequence features that might account for differences in VRC. The HIV-1
gag and pol genes are among the most conserved of the HIV-1 genome and in subtype
C viruses appear to drive replication capacity and clinical outcomes [14,20]. Moreover,
Gag-Pol chimeric viruses were shown to display similar VRC as the full-length HIV-1
genomes from which they were derived, supporting the idea that the Gag-Pol region was
a major determinant of VRC. A large analysis of the Gag-Pol region from East African
subtypes supported a hierarchy of inter-subtype recombinants replicating more highly
in vitro than subtype D, which was in turn higher than subtypes A or C and identified
changes in the Gag-p6 region that may play an important role among these chronically
infected individuals [21]. Insertions in Gag-p6 are associated with increased replication
as well as cooperation with protease resistance mutations [22–24]. Our study cohort
consisted of HIV-seronegative individuals in the International AIDS Vaccine Initiative
protocol C (IAVI protocol C) HIV epidemiology cohorts [25,26] who had been followed
until seroconversion with frequent sampling intervals that allowed us to identify the virus
near the time of transmission. We report here the molecular features of the Gag-Pol region
of a set of these viruses and the contribution of these features to VRC. The results are
important for determining the dynamics of HIV in human populations from East Africa
where subtypes A, D and A/D recombinants predominate and may help identify sequence
features associated with transmitted variants of distinct subtypes.
2. Materials and Methods
2.1. Study Subjects
This was a laboratory-based study incorporated into a larger multi-center primary
HIV-1 infection cohort (IAVI protocol C) through Clinical Research Centers in Uganda,
Kenya, Rwanda, Zambia and South Africa [26]. The protocol C study objectives were
to follow the immunologic, virologic and clinical parameters in HIV-infected volunteers
with a date of infection that could be accurately defined. In this study, data and samples
were obtained from Ugandan participants, all initially HIV negative. Individuals who
seroconverted were enrolled in IAVI protocol C. All were heterosexual individuals at high
risk from the general population and from HIV-1 sero-discordant couples. Participants
who became newly infected (tested positive for p24-antigen ELISA or HIV antibody) were
invited to enroll. The estimated date of HIV infection (EDI) was defined as the midpoint
between the last negative and first positive HIV antibody test, 14 days before the first
positive p24 antigen test, 10 days before the first positive viral load test in the absence of
p24 antigen or rapid HIV antibodies or the date of a self-reported high-risk exposure event.
All participants were seen monthly until 3 months after EDI, then quarterly until 24 months
and semi-annually thereafter. This study utilized protocol C stored plasma samples from
60 participants within 90 days post-EDI. The study received ethical approvals from the
Uganda National Council of Science and Technology (REF: HS 108) on 8 February 2006,
as well as from the UVRI Ethics Committee (REF: GC 127) on 9 December 2005. Study
participants had consented to their samples being stored and used for future studies after
approval by the relevant ethics committees.
2.2. Amplification and Sequencing Of Transmitted Virus for Identification of Early Gag-Pol Sequences
Viral RNA was isolated from 140 µL plasma using a QIA-amp Viral RNA Mini
Kit (Qiagen Inc, Valencia, CA, USA). RNA was either frozen at −80 ◦C or immedi-
ately used to synthesize cDNA using SuperScript IV (Invitrogen, Ljubljana, Slovenia).
Using a reverse primer 5FIV-R1 (5′-CTYTTTCTCCTGTATGCAGACCCC-3′; nucleotides
5272 to 5249 of the HXB2 sequence), cDNA was generated that served as a template to
amplify a 5 kb 5′ half viral genome fragment spanning the Gag-Pol region. For single
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genome amplification (SGA), the cDNA was serially diluted in replicates of eight and
subjected to nested PCR amplification with HIV-specific primers: 5FIV-R1 and RVDA-F1
(5′-GGGTCTCTCTDGTTAGACCAGAT-3′) for 1st round PCR and RVDA-F1 and 5FVR22
(5′-CCTAGTGGGATGTGTACTTCTGAAC-3′) for second round PCR. cDNA dilutions
that yielded >30% PCR positive wells were retested in 96-well plates to identify a dilu-
tion where <30% of wells were positive for amplification products; these procedures
and primers have been previously described in detail [27]. To ensure amplification
from single molecules and avoid in vitro PCR artefacts, 8–10 SGA amplicons were gen-
erated per patient and these were sequenced using di-deoxy sequencing technology
(Applied Biosystems 3500), aligned and analyzed using Sequencher and Geneious soft-
ware to infer an early infection consensus sequence. HIV-1 subtype classification was
done using the REGA (http://hivdb.stanford.edu/), the Recombination Identification
Program (RIP) (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html) and jpHMM
programs (GOBICS; University of Göttingen) [28–30] (Table 1). The jpHMM tool (http:
//jphmm.gobics.de/submission_hiv) was used to obtain recombination breakpoints, and
the recombinant HIV-1 drawing tool from Los Alamos National Laboratories (https:
//www.hiv.lanl.gov/content/sequence/DRAW_CRF/recom_mapper.html) was used to
generate the recombinant breakpoint maps.
2.3. Generation of Gag-Pol-NL4.3 Chimera Infectious Clones
The Gag-Pol amplicons were re-amplified with nested PCR with primers 5GagF:5′-
TAGAAGGAGAGAGATGGGTGCGAG-3′ and POL_REV1 5′-CCATGTGTTAATCCTCATC
CTGTC-3′ and cloned into an NL4.3 provirus backbone using the infusion homologous
recombination method (Clontech Takara kit, Krakow, Poland). HIV-1 Gag-Pol infectious
chimeric virus was packaged by transfection of 293T cells with pro-viral plasmids and
titrated using a TZM-bl indicator cell assay, as described [12].
2.4. In Vitro Assay for HIV-1 Replicative Capacity
To assess the VRC of Gag-Pol NL4.3 chimeras, 5 × 105 GXR25 cells [31] were infected
at a multiplicity of infection (MOI) of 0.05. GXR25 cells and chimeric viruses were incu-
bated with 5 µg/mL polybrene at 37 ◦C for 3 h, washed 5× with complete Roswell Park
Memorial Institute 1640 medium (RPMI) and plated into 24-well plates. Cells were split
1:2 to maintain confluency by replacement with an equal amount of fresh media. Viral
supernatants from days 2, 4, 6, 8 and 10 [32] and virions were quantified using a 33P-labeled
reverse transcriptase assay and the colorimetric assay, as described below. The optimal
window for logarithmic growth was determined to be between days 2–6. Replication
capacity values were generated by dividing the area under the curve (AUC) for days 2–6
of the chimeric viruses by the AUC of the NL4.3 wildtype after subtracting the negative
control [14]. Two independent Gag-Pol NL4.3 chimera clones per participant were run to
confirm cloning fidelity.
2.5. Quantification of HIV-1 Reverse Transcriptase Using Radioactive and Colorimetric Assays
Culture supernatant aliquots from infected cells were added to a reverse transcriptase
(RT) PCR master mix and incubated at 37 ◦C for 2 h; then the RT-PCR product was blotted
onto DE-81 paper and allowed to dry. Blots were washed 5× with Saline sodium citrate
buffer (SSC) and 3 times with 90% ethanol, allowed to dry and exposed to a phosphoscreen
overnight. Counts were read using a Cyclone Phosphorimager [32]. The reverse transcrip-
tase (RT) assay and colorimetric assay take advantage of the ability of reverse transcriptase
to synthesize DNA using the hybrid poly (A) × oligo (dT) 15 as a template and primer.
It avoids the use of [3H]- or [32P]-labeled nucleotides that are employed in standard RT
assays. In place of radiolabeled nucleotides, digoxigenin- and biotin-labeled nucleotides in
an optimized ratio are incorporated into the same DNA molecule by the RT activity. The
detection and quantification of the synthesized DNA as a parameter for RT activity follows
a sandwich ELISA protocol: biotin-labeled DNA binds to the surface of streptavidin-coated
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microplate modules. In the next step, an antibody to digoxigenin, conjugated to peroxidase
(anti-DIG-POD), is added and bound to the digoxigenin-labeled nucleotides (licensed by
Institut Pasteur). In the final step, the peroxidase substrate ABTS is added. The peroxidase
enzyme catalyzes the cleavage of the substrate to produce a colored reaction product.
The absorbance of the samples was determined using a microplate (ELISA) reader and
was directly correlated to the level of RT activity in the sample using the manufacturer’s
instructions (Sigma-Aldrich, Munich, Germany content version May 2016).
Table 1. Participants’ characteristics of 32 early infected Ugandans.
Participant
ID Subtype










191084 A1 0.21 Female 29 27 61,309 777
191637 A1 0.18 Male 31 85 26,595 634
191734 A1 0.35 Male 44 67 38,081 462
191918 A1 0.11 Male 22 56 8005 878
194180 A1 0.3 Male 46 59 37,767 438
270909 A1 0.22 Male 41 50 189,054 536
Mean * – – – 35.5 57.33 60,135 621
191996 D 0.53 Female 37 55 1599 806
192002 D 0.37 Female 27 50 2122 569
194020 D 0.55 Male 33 36 ND 783
194037 D 0.55 Male 34 51 33,550 531
194374 D 0.43 Male 33 35 31,954 401
194535 D 0.48 Male 39 47 ND 281
194603 D 0.58 Female 33 52 ND 887
194604 D 0.53 Female 35 44 69,512 677
270015 D 0.15 Male 58 11 14,064 355
270535 D 0.07 Male 31 73 5197 796
275026 D 0.46 Female 21 51 96,368 277
275031 D 0.44 Male 31 25 4260 795
194065 D 0.58 Male 41 42 20,890 470
Mean ** – – – 34.85 44 27,952 587
193008 A1D 1.34 Male 27 23 57,464 798
191639 A1D 0.47 Male 50 50 117,145 1149
191696 A1D 0.33 Male 29 50 239,477 398
191735 A1D 0.38 Male 22 56 2482 754
191923 A1D 1.11 Female 31 55 28,929 242
191955 A1D 0.76 Female 39 23 696 997
191997 A1D 0.97 Male 31 57 1002 764
194346 A1D 0.75 Male 29 31 415,426 346
194584 A1D 0.43 Female 33 25 7780 580
275027 A1D 0.73 Female 22 61 163,395 651
192018 A1C 0.96 Male 22 29 24,769 352
193006 CD 1.16 Male 24 52 47,355 478
270475 01AE 1.13 Female 28 43 14,528 531
Mean *** – – – 29.77 42.69 86,188 618
The most frequent subtype with the final designation; a final subtype designation was taken from the majority classification of the three
methods using Gag-Pol sequences. The 32 Gag-Pol sequences were analyzed with the following HIV subtype assignment tools: RIP
(http://www.hiv.lanl.gov/tent/sequence/RIP/RIP.html), REGA at http://hivdb.stanford.edu/ and jpHMM at http://jphmm.gobics.de.
Mean * denotes the mean for subtype A1, Mean ** denotes subtype D and Mean *** denotes recombinants. EDI—estimated date of HIV
infection, VRC—viral replicative capacity.
2.6. Protein Domain Methods
For the initial analysis, the encoded Pfam domains were identified using HMMER-
3.2.1 [33] (http://hmmer.org/) with the Pfam database (Pfam 32.0 September 2018,
(http://pfam.xfam.org/) [34]. For each sequence, all open reading frames ≥75 amino
acids were determined from both reading strands and examined for Pfam content. A
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domain hit was retained if the domain i-Evalue was <0.0001. Details of each domain
instance were gathered including position in query genome, length, domain i-Evalue and
bit score. For the analysis in Figure 5, all full or nearly full HIV-1 genomes were retrieved
from GenBank using the query (txid11676[Organism] AND 8000[SLEN]:11000[SLEN]) and
HIV-1 subtype classification was performed using the KAMERIS tool [35].
2.7. Additional
The Gag-Pol sequences described here have been deposited in GenBank with the
accession numbers MT027065-MT027082, MW316895-MW316901, MW316906-MW316908,
MW316914, MW316916, MW316920 and MW316924.
3. Results
3.1. Participant and Virus Characteristics
Thirty-two Ugandan protocol C participants had sequences successfully cloned from
early samples drawn within 90 days of EDI and had their VRC characterized. Table 1 shows
the participants’ characteristics. Three analysis tools, REGA, RIP and jpHMM [28–30] were
used to assign subtypes and identify possible recombinants. We observed 6 with subtype
A1, 13 with subtype D and 13 inter-subtype recombinants. The recombinants identified
were A1D (10), A1C (1), CD (1) and a complex recombinant of subtypes E, F1, G and A (1)
(Table 1, Figure 1).
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NL4.3 clone backbone [20,32]. The normalized VRC values of the chimeras for days 2–6 
(logarithmic growth phase of these viruses) relative to wildtype NL4.3 ranged from 0.07–
1.34 (Figure 2) The viral replicative capacity scores appeared to be biphasic, and accord-
ingly, we used two groups (LowVRC ≤ 0.8 and HighVRC ≥ 0.8). The results demonstrate 
that replacement with a novel Gag-Pol region can have measurable effects on the ability of 
the virus to replicate in cell culture. When sequences were arranged by VRC (Table 1), the 
subtype A1 sequences show the lowest VRC values while subtype D, followed by the re-
combinants, show higher VRC values. The subtype of the Gag-P6 region within each se-
quence (see Table 1) shows a pattern, with higher VRC values found in sequences with 
non-A1 Gag-P6 (Table 1) and the highest VRCs found in viruses with more complex Gag-
p6 regions. 
Figure 1. HIV-1 breakpoint map showing the recombination patterns across the 13 recombinants.
This was generated using the jpHMM website and recombinant HIV-1 drawing tool from the LANL
site as described in Mate ials and Methods. The key to color in the figure: red as A1, light green
as D, brown as C, dark green as G and light blue as 01_AE.
3.2. Gag-Pol-NL4.3 Chimeras Showed a Range of Replicative Capacities
VRC was measured using Gag-Pol chimeras of early virus Gag-Pol cloned into an
NL4.3 clone ba kbone [20,32]. The normalized VRC values of the chimeras for days 2–
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6 (logarithmic growth phase of these viruses) relative to wildtype NL4.3 ranged from
0.07–1.34 (Figure 2) The viral replicative capacity scores appeared to be biphasic, and
accordingly, we used two groups (LowVRC ≤ 0.8 and HighVRC ≥ 0.8). The results
demonstrate that replacement with a novel Gag-Pol region can have measurable effects on
the ability of the virus to replicate in cell culture. When sequences were arranged by VRC
(Table 1), the subtype A1 sequences show the lowest VRC values while subtype D, followed
by the recombinants, show higher VRC values. The subtype of the Gag-P6 region within
each sequence (see Table 1) shows a pattern, with higher VRC values found in sequences
with non-A1 Gag-P6 (Table 1) and the highest VRCs found in viruses with more complex
Gag-p6 regions.
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perhaps influencing replication capacity, we used Pfam profile hidden Markov models 
(profile HMMs) to document differences in functional protein domains encoded by the 
viruses. Profile HMMs provide a statistical description of protein domains or cleavage 
sites and can be used to identify domains as well as to document changes in domain se-
quences relative to a reference set [34,38]. The functional domains of HIV-1 are well stud-
ied and provide a good starting point to identify protein motifs whose variation might 
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no statistical correlation between the replication capacity of the Gag-Pol NL4.3 chimera
and SPVL in this cohort of subtype A1, D and A1D recombinants (Figure 3B). The time
taken for the CD4+ cell count to drop to less than 350 cells/µL between subtypes A1, D
and recombinants also showed no statistical difference (Figure 3A).
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3.4. Protein Domain Diversity of Gag-Pol Regions
To gain information about changes in viral protein functions associated with and
perhaps influencing replication capacity, we used Pfam profile hidden Markov models
(profile HMMs) to document differences in functional protein domains encoded by the
viruses. Profile HMMs provide a statistical description of protein domains or cleavage
sites and can be used to identify domains as well as to document changes in domain
sequences relative to a reference set [34,38]. The functional domains of HIV-1 are well
studied and provide a good starting point to identify protein motifs whose variation
might influence virus replication. The 13 domains from the HIV-1 Gag-Pol region are
described by Pfam, and preliminary results showed that seven domains (DUF935, zf-
CCHC_2, Gag-P6 in the gag protein and gag_asp_proteas, RVT_thumb, integrase_Zn, rve_3
in the Pol protein, marked in green and orange in Figure 4A) showed variation in the set of
32 sequences (Figure 4B).
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3.5. Variation of Gag-Pol Domains Linked to Elevated VRC
Using the Pfam domains [36] found in HIV-1 domains as guides, we prepared cus-
tom domains based on alignments from 391 subtype A1 complete genomes found in
GenBank (see Section 2.7). Using A1 as the reference domain set allowed us to detect
differences in the query sequences from the A1 type domains. For each of the 32 query
sequences, the instances of the seven domains within the query sequences were identified
and their domain bit scores (a measure of the distance of the query from the reference
Pfam domain) were collected. The major contributors to variation were the Gag-P6 domain
and the zinc finger CCHC domain, although modest changes were observed in the other
domains (Figure 4B).
Stratifying the Gag-Pol sequences into four subtype categories (A1, D, A1D and
Other_recombinants) revealed important patterns (Figure 3). In vitro replication as mea-
sured by VRC was clearly different across the four groups, with the non-recombinant
groups A1 and D showing lower VRC than the recombinants A1D and Other_Recombinants
(CD, A1C, A1AEF) (Figure 5A). Combined total Pfam bit scores of all seven domains were
calculated as a measure of how different the sequences were from the subtype A1 reference
set. When total scores were compared across the four groups, the reverse pattern was seen,
with the A1 sequences showing the highest scores (as expected, they were closest to the
subtype A1 reference set) and the other groups showing more distance from subtype A1
sequences (Figure 5B). Within the domains analyzed, the major contribution to the distance
score was in the Gag-P6 domain and, accordingly, the Gag-p6 scores showed a similar
pattern to the total score (Figure 5C).
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generality of Gag-P6 variation in HIV-1 biology, we expanded our analysis to include
all available HIV-1 full genome sequences. We asked if the observed Gag-P6 domain
variation occurred in HIV-1 genomes from chronic infections. To answer this question, all
available HIV-1 complete genome sequences were retrieved from GenBank (12,571 genomes,
30 October 2019) and classified by subtype. The majority of the HIV-1 genome sequences
in GenBank are expected to be derived from chronic infections due to acute infection (by
definition) being time-limited and the complexity of obtaining acute infection samples. For
all available near-full-length HIV genomes, subtypes were determined, the Gag-p6 Pfam
bit scores were determined and for each subtype, a median Gag-p6 Pfam bit score was
calculated. We then compared the 32 early Gag-p6 Pfam bit scores generated from the acute
infection study to the median values for the GenBank set of 12,571 genomes (Figure 7). We
found that 21 of the Gag-p6 bit scores fall below the median value for their corresponding
subtype (showing greater protein distance from the subtype A1 reference) and 14 of
32 scores fell below the interquartile range, the normal range of variation found in viruses
from chronic sequences (Figure 5). This shows increased variability (lower bit scores) in
the Gag-p6 domains of early infection sequences relative to the Gag-p6 domains from
chronic infections.

























Figure 7. Comparing Gag-P6 bit scores for early infection sequences and all available HIV-1 genomes. All available HIV-1
genome sequences were retrieved from GenBank and classified by subtype using the KAMERIS tool [37]. Gag-P6 Pfam
domains were identified and bit scores were gathered. The plot shows standard boxplots of the bit scores, stratified by
the 25 HIV-1 subtypes identified in the set of genomes, with first interquartile range indicated by a colored box and the
median value for each group indicated by a horizontal line. The Gag-P6 bit scores for the early sequences reported here are
shown with red markers in their corresponding subtype. The counts of genomes by subtype were subtype B:7186, C:1750,
01_AE:1092, A1:414, 02_AG:244, BF1:225, G:178, 01B:168, BC:161, U:122, A1D:108, A1C:105, D:101, A6:98, F1:93, 02A1:83,
CD:77, 01BC:72, O:71, BF:56, 07_BC:52, 08_BC:39, 11_cpx:29, A1CD:28, 35_AD:21, total: 12,573.
4. Discussion
In this study, we documented the VRC supported by Gag-Pol gene chimeras with
NL4.3 viruses generated from 32 Ugandan adults with very early HIV infection. The
study included the subtypes typically observed in Uganda, that is, subtype A, D and
A1D recombinants. The recombinant breakpoints greatly varied among the 13 recom-
binants identified in this study, as shown in Figure 1. Our results indicate that the set
of Gag-Pol genes described here support a range of VRCs, with some variants showing
a higher VRC than that of the wildtype NL4.3. In general, subtype A1 had the lowest
VRC, followed by subtype D, with inter-subtype recombinants having the greatest VRC.
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When looking at only the subtype classification of the Gag-p6 region (Figure 1), this is
consistent with earlier reports of inter-subtype differences in disease progression where
recombinants progressed fastest, followed by subtype D, with subtype A progressing the
slowest [9–11]. Our study results are also consistent with earlier studies that showed
inter-subtype recombinants having higher replicative fitness than pure subtypes [39,40] in
West Africa. Another study in East African cohorts showed a similar trend of hierarchy of
Gag protease-driven replication capacities, with subtypes A or C replicating less, followed
by D, and inter-subtype recombinants replicating the most [21].
Increasing evidence indicates that in vitro VRC appears to be a strong indicator of
HIV pathogenicity in the patient [14,20,41,42] Here, we observed that while there were
differences in VRC between subtypes A, D and recombinant Gag-pol, there was no correla-
tion between VRC and CD4+ cell count levels or viral load in the small number of patients
examined (results not shown). There was, however, a trend where most high replicators
progressed faster to CD4+ counts of less than 350 cells/µL in the first 5 years of infection,
although this was not statistically significant. However, no trends or significant correlations
between SPVL and VRC were observed (results not shown). This suggests that the VRC of
the initial infecting strain may have limited impact on these important long-term markers
of HIV pathogenesis.
To gain information about viral protein functions that might be associated with the
observed differences in replication capacity, we monitored changes in the Pfam profile
hidden Markov models found in these sequences to reveal differences in functional or
defined protein domains in the Gag-Pol genes. Rather than categorizing VRC by general
subtype, the domain analysis we performed provided a more detailed focus on changes
in protein domains with functional attributes. Across the set of 32 sequences, there was
variability in three domains in the Gag coding region: a domain of unknown function
DUF935 in the amino terminal half of the protein, the zinc finger motif zf_CCHC_2 and the
gag-p6 domain near the C-terminus and overlapping with the Pol coding region. Gag-p6 is
a major phosphoprotein of HIV-1 that has been shown to play an important role when it
comes to release of the virus from the infected cells [43]. The four viruses with the highest
VRCs showed the greatest level of variety in the Gag-p6 domain (lowest HMM bit score),
suggesting that changes in this domain may influence viral replication. Two sequences had
insertions related to a PYxE insert previously observed in subtype C viruses with elevated
virulence [44]. The PYxE motif may be involved in the ALIX (ALG-2 (apoptosis-linked gene
2)-interacting protein X)-mediated virus release pathway [45] and recently the insertion
of this tetrapeptide has been implicated in the restoration of Gag binding to ALIX with
enhanced viral fitness in the presence or absence of lopinavir and tenofovir alafenamide
antiretroviral drugs [23].
The HIV-1 nucleocapsid protein carries two zinc fingers and is located at the C-
terminus of Gag, trailed by the p6 domain. The zf-CCHC_2 domain is one of the two
zinc finger domains in the Gag nucleocapsid protein and both are required for protein
localization, genomic RNA binding and encapsidation [46–48]. All zinc finger changes
or mutations in one study were shown to negatively impact on virus replication and
maturation [49]. The gag-p6 domain is needed for particle budding, during which the viral
particles pinch off from the cellular membrane [50]. The p6 domain additionally contains
proline-rich and di-leucine areas, which are the target of the cellular proteins Tsg101 and
Alix, respectively, which are involved in the cellular class E protein sorting pathway and
HIV-1 budding machinery [51,52].
We asked if the observed Gag-P6 domain variants were unique to incident viruses
or if similar variation can be observed in HIV-1 genomes derived from chronic infection.
We examined the Gag-P6 domain from all available full or nearly full genomes from
GenBank (Figure 5). Comparing the Gag-P6 bit scores (a measure of the distance of the
query sequence to the reference domain) to median scores for each HIV-1 subtype showed
that 21 of the early infection sequences had Gag-P6 bit scores below the median value
for their subtype (Figure 5). Lower Gag-P6 bit scores indicate greater variation from the
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A1 reference domain, thus there is a tendency for changes in the Gag-P6 sequences. The
Gag-P6 region is emerging as an important determinant of HIV-1 replication [23,44,45].
Although it seems unlikely that a Gag-P6 variant unique to early infection sequences exists,
the increased variation in this site observed in this small set of 32 patients is consistent with
the domain playing a role in transmission. It is also notable that additional changes were
observed in six other Gag-Pol domains (Figure 2 and these may cooperate with the Gag-p6
alterations in viruses associated with transmission.
The first proline in the Gag-P6 motif is part of the protease cleavage site 5′ to Gag-P6
and seven of the eight low VRC sequences have a proline at this site (cleavage site FP) while
there is leucine (cleavage site FL) in the majority of the medium and high VRC sequences
(Figure 4). Similarly, low VRC sequences have either a proline or cysteine at position 36
near to the carboxy-terminal cleavage site flanking the Gag-P6 domain. These changes to or
from proline near essential protease cleavage sites may play important roles in determining
the efficiency of Gag polyprotein processing, which in turn influences the viral packaging
and viral load and perhaps plays an important role in establishing early infection. It should
be noted that the proline to serine or proline to leucine coding changes require only a
1 nt change and may account for the diversity observed at this site. One can speculate that
as infections progress to a chronic stage, it may be useful to reduce viral loads to avoid
immune responses and simple amino acid switches might be involved.
Our study had some limitations. The effort required for SGA cloning limited the
number of sequences available. The VRC measurement is a simplified virus replication in
the absence of immune responses and the measurements were performed using a query
Gag-Pol sequence within an HXB2 backbone virus. This potentially misses more complex
interactions between the Gag-Pol region and the rest of the virus. However, despite the
modest sample size, we were still able to observe strong differences in VRC by HIV-1
subtype. The samples were obtained in 2006–2011 and HIV-1 evolution has continued.
However, the global analysis shown in Figure 5 included more recent sequence data up
to December 2019 and the Gag-p6 variations we observed in the set of 32 early infection
sequences appeared to be representative of the entire HIV-1 epidemic.
In conclusion, the current study has revealed crucial features of the HIV-1 Gag-Pol
region, especially the Gag-p6 domain that influences viral replicative capacity and may
play a role in establishing new HIV-1 infections.
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